CONJUPRI

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CONJUPRI (CONJUPRI).

How it works

Selective vasopressin V1a receptor antagonist, inhibiting vasopressin-mediated smooth muscle contraction in arterioles, leading to vasodilation and reduced portal pressure.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4 and CYP2C19; minor renal excretion.
Excretion	Primarily hepatic metabolism via CYP3A4, with 80-90% excreted as metabolites in feces (biliary) and 10-20% in urine as unchanged drug or metabolites.
Half-life	Terminal elimination half-life is approximately 9-16 hours (mean 12 hours) in healthy volunteers, supporting once-daily dosing. Half-life may be prolonged in patients with mild-to-moderate hepatic impairment.
Protein binding	Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 50 L (0.7-1.0 L/kg), indicating extensive extravascular distribution. High Vd suggests significant tissue binding.
Bioavailability	Absolute bioavailability is approximately 30% (range 20-40%) due to extensive first-pass metabolism. Food does not significantly affect bioavailability.
Onset of Action	Oral administration: Onset of antihypertensive effect occurs within 2-4 hours post-dose, with peak effect typically observed at 6-12 hours.
Duration of Action	Duration of antihypertensive effect is approximately 24 hours, allowing for once-daily dosing. Clinical trials demonstrated sustained blood pressure reduction over the dosing interval.

Classification & Brands

Dosing & administration

Adults: Initial 10 mg orally once daily, titrate to 20-40 mg once daily. Maximum 40 mg/day.

Dosage form	TABLET
Renal impairment	eGFR 30-60 mL/min: No adjustment; eGFR <30 mL/min: Not recommended (insufficient data).
Liver impairment	Child-Pugh A (mild): No adjustment; Child-Pugh B or C: Contraindicated.
Pediatric use	Safety and efficacy not established in pediatric patients.
Geriatric use	Start at lower end of dosing range (10 mg daily) due to increased sensitivity; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CONJUPRI (CONJUPRI).

Breastfeeding

Excreted in human milk; estimated infant dose <5% of maternal weight-adjusted dose; M/P ratio not established. No adverse effects reported in infants. American Academy of Pediatrics considers amlodipine compatible with breastfeeding. Monitor infant for hypotension and bradycardia.

Teratogenic Risk

Conjupri (levamlodipine) is an S-enantiomer of amlodipine. Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, calcium channel blockers may cause fetal hypoxia, IUGR, and preterm delivery due to maternal hypotension. Risk in first trimester is low; second/third trimester: potential fetal risks include reduced uteroplacental perfusion, fetal distress, and neonatal hypotension. Use only if maternal benefit outweighs fetal risk.

Warnings & precautions

■ FDA Black Box Warning

WARNING: RISK OF SERIOUS HYPOTENSION AND HYPOVOLEMIA. Monitor hemodynamics closely; discontinue or adjust dose if hypotension occurs.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to conivaptan or any component","Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)"]

Clinical Precautions

Precautions

["Hypotension/Hypovolemia","Cardiac ischemia","Electrolyte imbalances (hyperkalemia, hyponatremia)","Hepatic encephalopathy","Monitor renal function and blood pressure"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

CONJUPRI

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CONJUPRI (CONJUPRI).

How it works

Selective vasopressin V1a receptor antagonist, inhibiting vasopressin-mediated smooth muscle contraction in arterioles, leading to vasodilation and reduced portal pressure.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4 and CYP2C19; minor renal excretion.
Excretion	Primarily hepatic metabolism via CYP3A4, with 80-90% excreted as metabolites in feces (biliary) and 10-20% in urine as unchanged drug or metabolites.
Half-life	Terminal elimination half-life is approximately 9-16 hours (mean 12 hours) in healthy volunteers, supporting once-daily dosing. Half-life may be prolonged in patients with mild-to-moderate hepatic impairment.
Protein binding	Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 50 L (0.7-1.0 L/kg), indicating extensive extravascular distribution. High Vd suggests significant tissue binding.
Bioavailability	Absolute bioavailability is approximately 30% (range 20-40%) due to extensive first-pass metabolism. Food does not significantly affect bioavailability.
Onset of Action	Oral administration: Onset of antihypertensive effect occurs within 2-4 hours post-dose, with peak effect typically observed at 6-12 hours.
Duration of Action	Duration of antihypertensive effect is approximately 24 hours, allowing for once-daily dosing. Clinical trials demonstrated sustained blood pressure reduction over the dosing interval.

Classification & Brands

Dosing & administration

Adults: Initial 10 mg orally once daily, titrate to 20-40 mg once daily. Maximum 40 mg/day.

Dosage form	TABLET
Renal impairment	eGFR 30-60 mL/min: No adjustment; eGFR <30 mL/min: Not recommended (insufficient data).
Liver impairment	Child-Pugh A (mild): No adjustment; Child-Pugh B or C: Contraindicated.
Pediatric use	Safety and efficacy not established in pediatric patients.
Geriatric use	Start at lower end of dosing range (10 mg daily) due to increased sensitivity; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CONJUPRI (CONJUPRI).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

WARNING: RISK OF SERIOUS HYPOTENSION AND HYPOVOLEMIA. Monitor hemodynamics closely; discontinue or adjust dose if hypotension occurs.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to conivaptan or any component","Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)"]

Clinical Precautions

Precautions

["Hypotension/Hypovolemia","Cardiac ischemia","Electrolyte imbalances (hyperkalemia, hyponatremia)","Hepatic encephalopathy","Monitor renal function and blood pressure"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…